Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
65 Cards in this Set
- Front
- Back
|
Nitrogen Mustards
|
Mechlorethamine, Cyclophosphamide, Chlorambucil
|
|
|
Nitrosoureas
|
Carmustine
|
|
|
Alkyl Sulfonate
|
Busulfan
|
|
|
Trizaenes
|
Dacarbazine
|
|
|
Platinum Compounds
|
Cisplatin, Carboplatin, Oxaliplatin
|
|
|
Intrinsically reactive
|
mechlorethamine, carmustine, busulfan, chlorambucil, platniums
|
|
|
require metabolic activation
|
cyclophosphamide
|
|
|
Fold Acid Analogs
|
Methotrexate, Pemtrexed
|
|
|
Pyrimidine Analogs
|
Fluorouracil, Capecitabine, Cytarabine, Gemcitabine
|
|
|
Purine Analogs
|
Mercaptopurine
|
|
|
Microtubule Agents
|
Vinca Alkaloids: Vinblastin, Vincristine, Vinorelbine
Paclitacel Doxetacel |
|
|
Topoiomerase Agents
|
Etoposide, Teniposide
Irinotecan, Topotecan |
|
|
Abx Agents
|
Dactinomycin, Doxorubicin, Idarubcin Mitoxantrone, Bleomycin
|
|
|
Alkylating Agents MOA
|
Crosslinking of DNa, and alkylation of DNA and/or protein. Strong electrophiles. DNA damage
Activation in alkaline or neutral pH solution. |
|
|
Cisplatin
|
Broad Activity
epithelial Malignancies Platinum |
|
|
Carboplatin
|
ovarian cancer
|
|
|
Oxaliplatin
|
More effective: DNA repair enazyme proficients cells are effected. Wide range: ovarian and cerivical
|
|
|
Methotrexate
|
Inhibits DHFR, inhibits folate dependent enzyme,
|
|
|
Pemtrexed
|
Multi-targeted Antifolate. Inhibits DHFR and thymidylate and purine synthesis.
Colon, mesothelioma and NSCLC |
|
|
Capecitabine
|
Most important 5-FU. Colon and Breast. good for tumors w increase thymadine phosphorylase activity.
|
|
|
Pyrimidine Analogs MOA
|
several pathways: fluorouracil is converted in vivo to F-dUMP that irreversibly inhibits thymidylate synthase.
|
|
|
cytrabine
|
potent inhibitor DNA polymerase and DNA elongation.
Acute myclotic leukemia, induction and remission of disease |
|
|
Gemcitabine
|
metastatic pancreatic
NSCLC |
|
|
Mercaptopurine
|
inhibits multiple pathways: conversion of inosine monophosphate to adenine and guanine. Must be activated to necleotide form by HGPRT
melignant disease, immunosupression and anti-viral |
|
|
Fludarabine
|
D"A chain termination and induction of apoptosis. Incorperated into DNA and RNA
Chronic lympocytic leukemia and low grade lymphoma |
|
|
Hydroxyurea
|
inhibits ribonucleotide reductase.
|
|
|
Vinblastin and Vincristine
|
blocks cells in mitosis! inhibits ability of protein to polymerize into microtubules
Leukemia, Leymphoma, testicualr |
|
|
Vinocrelbine
|
lung and breast
|
|
|
Paclitaxel, Docetaxel
|
Promote polymerization of microtubules-> aberrant structures.
|
|
|
Etoposide, Teniposide
|
TOPO II, double stand break. Pediatric leukemia, SCLC, testicular cancer
|
|
|
Topotecan, Irinotecan
|
TOPO I, colorectal, ovarian and SCLC
|
|
|
Dactinomycin
|
binds to double helical DNA, block transcription
|
|
|
Doxorubicin, Idarbucin
|
Cardiotoxicity! important anti-tumor agents. Isolated from fungus. TOPO II
|
|
|
Mitoxantrone
|
DNA strand break via TOPO II
prostate and leukemia. Less cardiotoxic than doxorubicin |
|
|
Bleomycin
|
cytotic action via oxidative damange, double and single strand breaks.
Squamous carcinomas of cervix, head, neck and lungs. Lymphomas and testicular tumors. Cutaneous and pulm side effects. role in combination therapy. |
|
|
Big Four Cancers
|
Prostate
Breast Lung Colorectal |
|
|
Available Effective Screening
|
Colorectal
Breast prostate cervical skin tesiticular oral |
|
|
Stage I
|
limited to tissue of origin
|
|
|
Stage II
|
lymph node involvement and/or large or multiple tumors in tissue of origin
|
|
|
Stage III
|
bulky localized disease +/- lymph node involvement
|
|
|
Stage IV
|
metastatic disease
|
|
|
tamoxifen
|
Nolvadex
Well abs, distributes to most tissues. Plasma protein bound. Liver Met, little rena. half: 7-14days 20 mg QD |
|
|
Fluvestrant
|
Faslodex
Not orally abs: IM knection. Wide dist. Plasma protein bound. Liver met, renal excretion 1%, half: 40 days 250 mg Q month |
|
|
flutamide
|
eulixin
250 mg TID |
|
|
Bicalutamide
|
Casodex
50 mg QD |
|
|
Anestrozol, Letrozol
|
Arimideg 1 mg, Fenecria 2.5 mg QD
Well Abs, Dist well. liver met. A: Feeces L: Urine. half: 2 days. |
|
|
Exemtance
|
Aromatin 25 mg QD
Liver met, fecal elim. half 1 day. Irreversible. |
|
|
Nilutamide
|
nilandron 300 mg QD, 150 mg QD
half: 41-49 hours |
|
|
Leuprolide
|
Lupron, Eligard, Viadur 22.5 mg SC Q 3 months.
50% protein bound, not orally abs, excreted in urine. half: 3-5 hours |
|
|
Goserelin
|
Zoladex. 3.6 mg SC q 28 days, or 10.8 mg SC q 90 days
|
|
|
Abarelix
|
Plenaxis, life threatening allergic reaction.
|
|
|
Degarelix
|
GnRH antagoinst, weight increase, increase transaminase.
|
|
|
Rituximab
|
Rituxan
mAb against CD20 on B cells. Non Hodgkins lymphmoa, Pre-medicated |
|
|
Trastuzimab
|
Herceptin
humanzide mAb to HER2 Cardiac dysfunction. |
|
|
Cetuximab
|
Erbitux. Chimeric mAb against EGFR
Pre medicate Colon Cancer, head or neck cancer |
|
|
Bevacizumab
|
Avastin
humanized mAb to VEGF Colon, Lung, Breast |
|
|
Panitumumab
|
Vectibix
human mAB against EGFR Colon Cancer |
|
|
Ibritumomab-yttrium-90
|
ZevaIin
Murin mAB linked to yttrium 90 directed against CD20 lymphoma |
|
|
Tositumomab-iodine
|
bexxar
Murine mAB linked to iodine 131 agains CD 20 lymphoma |
|
|
Erlotinib, Gefitinib
|
Tarceva, Iressa
EGFR/HER1 inhibotr E: 150 mg QD, lung and pancreatic G: 250-500 mg QD, lung |
|
|
Lapatinib
|
tykerb.
EGFR/HER1 and EGFR/HER2 TK inhibitor. Breast cancer 1250mg QD |
|
|
Sorafenib
|
Nexavar. RAF, KIT, VEGF and PDGF tyrosine kinase inhibitor. Renal cell cancer. 400 mg BID w/o food
|
|
|
Imatinib
|
Gleevec. 400-800 mg Q/BID
Bcr-Abl inhibitor Chronic Myleiod leukemia |
|
|
Dasatinib
|
Sprycel
70 mg BID. Bcr-Abl inhibitor chronic myloid leukemia |
|
|
Nilotinib
|
Tasigna
400 mg BID |
